Second Generation Farnesyl Transferase Inhibitors
- Summary
- Purdue University researchers have developed a strategy for intracellular delivery of the monophosphates of such FT inhibitors, which could provide an effective therapeutic approach.
- Technology Benefits
- Intracellular delivery of inhibitorsEnables absolute quantification of known compounds and relative quantification of unknown compounds in most cases using a single liquid chromatography-mass spectrometry (LC-MS) run
- Technology Application
- Cancer TreatmentMedical/HealthcareBiotechnology
- Detailed Technology Description
- Richard BorchPurdue Medicinal Chemistry and Molecular Pharmacology
- Countries
- United States
- Application No.
- 8,324,378
- *Abstract
-
- *Background
- A type of mutated constitutively active protein, Ras, is seen in a significant number of cancers. There is a great deal of interest in preventing the Ras protein from localizing on cell membranes as an anticancer treatment. One way to prevent localization is to inhibit farnesyltransferase (FTase), the enzyme responsible for facilitating Ras attachment to the cell membrane. Traditional FTase inhibitors are highly charged and incapable of traversing the cell membrane to enter the cell.
- *IP Issue Date
- Dec 4, 2012
- *IP Type
- Utility
- *Stage of Development
- Proof of Concept
- *Web Links
- Purdue Office of Technology CommercializationPurdueInnovation and EntrepreneurshipRichard BorchPurdue Medicinal Chemistry and Molecular Pharmacology
- Country/Region
- USA
For more information, please click Here
